ASEAN and China Biosimilars Market Anticipated to Reach $5,506.2 million by 2025

The ASEAN and China Biosimilars Market report categories the market by globally based on size, share, Revenue, key manufacturers, regions, type and application with in depth descriptions.

ASEAN and China Biosimilars Market Overview:

The ASEAN and China Biosimilars Market was valued at $687.6 million in 2017 and is expected to reach $5,506.2 million by 2025 with a CAGR of 29.7% during the forecast period. Biosimilars or follow-on-biologics are the “copied” version of reference biologics, which are protected by intellectual rights that are anticipated to expire in future. The development and validation of biosimilars with reference biologics is a crucial part of the overall process. The key driving factor for biosimilars is their implied ability of providing more cost-effective treatment than branded biologics.

Key players operating in the pharmaceuticals industry are largely investing in the development of biosimilars that can be applied for the treatment of several chronic medical conditions. Biosimilars have the potential to offer up to 30% cost reduction as compared to branded biologics. This is attributed to the compact validation pathways that reduce the additional cost of clinical trials, which further assist manufacturers to achieve scale economies. The key contributing factor to the growth in demand for biosimilars across the ASEAN and Chinese market is the patent expiration of most of the blockbuster drugs in the past few years. However, the biosimilars industry is witnessing issues pertaining to achieving product efficiency while maintaining the required production capacity. This plays a pivotal role in the biosimilars industry considering the large population of ASEAN countries along with China. Progress in improving the product efficiency and quantity is expected to open new avenues for the expansion of the biosimilars market across ASEAN and China.

Get Free Sample Copy Of This Report @

The ASEAN and China biosimilars market is segmented into molecule type, application, and region. Based on molecule type, the market is divided into human growth hormone, erythropoietin, monoclonal antibodies, insulin, interferon, granulocyte-colony stimulating factor, and peptide. Based on application, the market is classified into blood disorders, oncology diseases, chronic and autoimmune diseases, growth hormone deficiency, and others. Further, the chronic and autoimmune diseases segment is sub-categorized into diabetes, rheumatoid arthritis (RA), glaucoma, and others. Based on region, the market is analyzed across China and ASEAN region.

Key Benefits ASEAN and China Biosimilars Market:

  • The study provides an in-depth analysis of the ASEAN and China biosimilars market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • A quantitative analysis from 2017 to 2025 is discussed to enable the stakeholders to capitalize on the prevailing market opportunities.
  • A qualitative analysis of the driving factors and opportunities help analyze the competitive scenario of the market.
  • Porter’s five forces analysis is provided to interpret the bargaining power of the suppliers & buyers, threat of new entrants & substitutes, and competition among the key players.

Get Discount Copy Of This Report @

ASEAN and China Biosimilars Key Market Segments:

By Molecule Type

  • Human Growth Hormone
  • Erythropoietin
  • Monoclonal Antibody
  • Insulin
  • Interferon
  • Granulocyte-Colony Stimulating Factor
  • Peptide

By Application

  • Blood Disorders
  • Oncology Diseases
  • Chronic and Autoimmune Diseases
  1. Rheumatoid Arthritis (RA)
  2. Diabetes
  3. Glaucoma
  4. Others
  • Growth Hormone Deficiency
  • Others

By Region

  • China
  • ASEAN Region
  1. Singapore
  2. Malaysia
  3. Thailand
  4. Indonesia
  5. Philippines
  6. Vietnam
  7. Rest of ASEAN Countries

Key Market Players

  • 3SBIO Inc.
  • Qilu Pharmaceutical
  • Novartis International AG (Sandoz International GmbH)
  • Pfizer Inc. (Hospira)
  • STADA Arzneimittel
  • Beijing SL Pharmaceutical Co., Ltd.
  • Fosun Pharmaceutical (Shanghai Fosun Pharmaceutical Co., Ltd.)
  • Amgen Inc.
  • AstraZeneca Plc
  • Teva Pharmaceutical Industries Ltd.



Related Report:

GLOBAL CORD BLOOD BANKING SERVICES (STEM CELL) MARKET , Size, Share, Trends, Forecast, Global Analysis, Research, Report, Segmentation, And Future Demand, 2012 – 2020

Umbilical cord blood bank is storage facility that collects cord blood after the childbirth from placenta. Cord blood is rich source of stem cell used in treatment of different chronic diseases. Private and public cord blood banks are the two major types of banks that are prevalent in the cord blood bank market. Cord blood market is expected to grow at 33.5% CAGR from 2012-2020. Public cord blood banks share more revenue as compared to private cord blood banks…..

Read More

About Us:

Big Market Research has a range of research reports of various domains across the world. Our database of reports of various market categories and sub-categories would help to find the exact report you may be looking for.

Contact Us:

Mr. Abhishek Paliwal

Big Market Research2

5933 NE Win Sivers Drive, #205, Portland,

OR 97220 United States

Direct: +1-971-202-1575

Toll Free: +1-800-910-6452




Sumedh Raj

Sumedh is a content marketing coordinator and social media manager for The Innovative Reports and Market Research Analyst. Sumedh holds a Bachelor's Degree in Communications and Public Relations from University of Pune and offers many years of experience in various forms of writing. Some of her favorite hobbies include exploring new music, creative writing and spending time with his dogs.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *